No significant differences in hematological or serum biochemical parameters were observed between any treatment group and the control group (Additional file 2: Tables S8S9)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
Epitalon is the spelling used in FDAs 2026 assessment and many scientific publications
There is increasing interest in developing tripeptides with targeted therapeutic functions, particularly for applications in wound healing [36, 75, 92], as well as in cancer [60, 170], neurodegenerative [24, 173], and cardiovascular diseases [177, 178], and in the design of functional foods [179, 182, 188]
Its potential as an anti-cancer drug is yet to be explored, but results from research so far look promising